PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32516834-4 2020 RESULTS: Densities of CD3+ and CD8+ TILs and PD-L1 expressions on TCs and ICs were significantly higher in p16+/HPV-mediated OPSCC. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 66-69 CD274 molecule Homo sapiens 45-50 33380650-11 2020 Nearly 55.7% (n = 39) of the TCs tested positive for PD-L1 expression. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 29-32 CD274 molecule Homo sapiens 53-58 31872892-5 2020 RESULTS: With the 22C3, SP142, and E1L3N assays, positive PD-L1 expression on TCs >=1% was observed in 24 (4.1%), 12 (2.0%), and 16 (2.7%) cases and on ICs >=1% was observed in 132 (22.3%), 120 (20.3%), and 65 (11.0%) cases, respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 78-81 CD274 molecule Homo sapiens 58-63 31872892-9 2020 PD-L1 expression on TCs was associated with papillary type 2 RCC (P <0.001). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 31959546-12 2020 The frequencies of PD-L1 expression in both TCs and TILs was higher in UC and SCC (both 30%) than in ACB (18%). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 44-47 CD274 molecule Homo sapiens 19-24 31897588-4 2020 High PD-L1 expression in TCs and TIICs was defined as >= 50% of stained cells. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 25-28 CD274 molecule Homo sapiens 5-10 31897588-5 2020 RESULTS: There was a significant difference in 18F-FDG uptake according to the PD-L1 status in TCs and TIICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 95-98 CD274 molecule Homo sapiens 79-84 31897588-8 2020 CONCLUSIONS: 18F-FDG uptake in NPC lesions was positively correlated with PD-L1 expression in TCs and negatively correlated with PD-L1 expression in TIICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 94-97 CD274 molecule Homo sapiens 74-79 30411509-3 2020 In each case, we employed two methods-intensity and proportion scores-to evaluate PD-L1 expression in TCs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 102-105 CD274 molecule Homo sapiens 82-87 30411509-11 2020 CONCLUSIONS: The results suggested that high intensity of PD-L1 expression in TCs is associated with lymph node metastasis in cSCC. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 78-81 CD274 molecule Homo sapiens 58-63 31359214-7 2019 PD-L1+ TCs were significantly associated with shorter disease-free survival (DFS, HR = 1.43, 95% CI 1.21-1.70, P < 0.0001) and overall survival (OS, HR = 1.58, 95% CI 1.14-2.20, P = 0.006). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 7-10 CD274 molecule Homo sapiens 0-5 31343994-5 2020 In addition, among the remaining 47 (81%) "PD-L1 tumors," we nevertheless also identified "PD-L1 FOV" (ie, "field of view" of about 3 mm2 containing >=1% positive TCs) in 22 (38%) additional tumors. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 163-166 CD274 molecule Homo sapiens 91-96 31359214-10 2019 CONCLUSION: PD-L1 expression on TCs associates with high-risk clinicopathological parameters and poor prognosis in PBC patients, while PD-L1+ TILs may relate to a better survival. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 32-35 CD274 molecule Homo sapiens 12-17 30449485-4 2018 The percentages of PD-L1-positive TCs and ICs in lung metastases and the primary tumor were classified into five categories (0: <1%; 1: 1%-4%; 2: 5%-9%; 3: 10%-49%; and 4: >=50%). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 34-37 CD274 molecule Homo sapiens 19-24 31366557-5 2019 However, PD-L1 expression on TCs or ICs, and CD8+ TIL density, was not significantly associated with patient survival in ESCC patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 29-32 CD274 molecule Homo sapiens 9-14 31129768-8 2019 The number of patients with PD-L1 expression on TCs, stromal TIICs and intraepithelial TIICs was 13 (5.5%), 64 (26.9%) and 45 (18.9%), respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 48-51 CD274 molecule Homo sapiens 28-33 31129768-10 2019 PD-L1-expressing TCs were an independent marker of poor prognosis [hazard ratio (HR) = 3.387, P = 0.003], and PD-L1-expressing stromal TIICs were an independent marker of good prognosis (HR = 0.551, P < 0.001). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 17-20 CD274 molecule Homo sapiens 0-5 31129768-11 2019 CONCLUSIONS: PD-L1-expressing TCs were a marker of poor prognosis; in contrast, PD-L1-expressing TIICs were a marker of good prognosis. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 30-33 CD274 molecule Homo sapiens 13-18 31019901-10 2019 However, PD-L1 expression in TCs was not significantly different between pre- and post-sorafenib tissues (IHC 0/1/2/3: 19/2/0/2 vs. 14/5/0/4, p = 0.094). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 29-32 CD274 molecule Homo sapiens 9-14 30253973-15 2019 Our results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 104-107 CD274 molecule Homo sapiens 45-50 29672367-7 2018 PD-L1 was expressed in >=1% of tumor cells (TCs) in 69% of patients, in >=50% of TCs in 12% of patients, and in >=5% of either TCs or infiltrating immune cells in 71% of patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 47-50 CD274 molecule Homo sapiens 0-5 29672367-7 2018 PD-L1 was expressed in >=1% of tumor cells (TCs) in 69% of patients, in >=50% of TCs in 12% of patients, and in >=5% of either TCs or infiltrating immune cells in 71% of patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 87-90 CD274 molecule Homo sapiens 0-5 29672367-7 2018 PD-L1 was expressed in >=1% of tumor cells (TCs) in 69% of patients, in >=50% of TCs in 12% of patients, and in >=5% of either TCs or infiltrating immune cells in 71% of patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 87-90 CD274 molecule Homo sapiens 0-5 31260834-7 2019 The optimal number of TCs to match PD-L1<1%/>=1% between Max-TCs and Mini-TCs was 100 (sensitivity: 0.676, 1 - specificity: 0.333). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 22-25 CD274 molecule Homo sapiens 35-40 31260834-7 2019 The optimal number of TCs to match PD-L1<1%/>=1% between Max-TCs and Mini-TCs was 100 (sensitivity: 0.676, 1 - specificity: 0.333). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 67-70 CD274 molecule Homo sapiens 35-40 31260834-7 2019 The optimal number of TCs to match PD-L1<1%/>=1% between Max-TCs and Mini-TCs was 100 (sensitivity: 0.676, 1 - specificity: 0.333). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 67-70 CD274 molecule Homo sapiens 35-40 31260834-8 2019 PD-L1>=1% in Mini-TCs containing >=100 TCs was associated with longer progression-free survival (PFS; median 7.6 vs 1.8 months, P<0.01) and overall survival (OS; median Not Reached vs 9.9 months, P=0.04) compared with PD-L1<1%. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 21-24 CD274 molecule Homo sapiens 0-5 31260834-8 2019 PD-L1>=1% in Mini-TCs containing >=100 TCs was associated with longer progression-free survival (PFS; median 7.6 vs 1.8 months, P<0.01) and overall survival (OS; median Not Reached vs 9.9 months, P=0.04) compared with PD-L1<1%. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 21-24 CD274 molecule Homo sapiens 227-232 31260834-8 2019 PD-L1>=1% in Mini-TCs containing >=100 TCs was associated with longer progression-free survival (PFS; median 7.6 vs 1.8 months, P<0.01) and overall survival (OS; median Not Reached vs 9.9 months, P=0.04) compared with PD-L1<1%. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 45-48 CD274 molecule Homo sapiens 0-5 31260834-8 2019 PD-L1>=1% in Mini-TCs containing >=100 TCs was associated with longer progression-free survival (PFS; median 7.6 vs 1.8 months, P<0.01) and overall survival (OS; median Not Reached vs 9.9 months, P=0.04) compared with PD-L1<1%. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 45-48 CD274 molecule Homo sapiens 227-232 31499335-2 2019 However, the mechanistic and clinical significance of the effect of PD-L1 on TCs versus ICs remains unclear. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 77-80 CD274 molecule Homo sapiens 68-73 31499335-4 2019 METHODS: We evaluated PD-L1 expression on TCs and ICs using Ventana SP263 assay and the stromal M2 TAM distribution using CD163 staining in 160 consecutive patients with resected non-small cell lung cancer (NSCLC). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 42-45 CD274 molecule Homo sapiens 22-27 31499335-5 2019 RESULTS: PD-L1 expression on TCs and ICs was significantly higher in stromal M2 TAM-high group than in stromal M2 TAM-low group (p < 0.001 and p < 0.001, respectively). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 29-32 CD274 molecule Homo sapiens 9-14 31499335-6 2019 Regarding the clinical significance of PD-L1, PD-L1 expression on TCs was significantly associated with histology (p = 0.001), tumor differentiation (p < 0.001) and nodal status (p = 0.029). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 66-69 CD274 molecule Homo sapiens 39-44 31499335-6 2019 Regarding the clinical significance of PD-L1, PD-L1 expression on TCs was significantly associated with histology (p = 0.001), tumor differentiation (p < 0.001) and nodal status (p = 0.029). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 66-69 CD274 molecule Homo sapiens 46-51 31499335-10 2019 CONCLUSIONS: During tumor progression in NSCLC, the presence of M2 TAMs might affect PD-L1 expression both on TCs and ICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 110-113 CD274 molecule Homo sapiens 85-90 31499335-11 2019 In patients with NSCLC, PD-L1 expression both on TCs and ICs was associated with malignant behaviors, which was more in case of ICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 49-52 CD274 molecule Homo sapiens 24-29 31190987-7 2019 PD-L1 expression on TCs was associated with worse overall survival (HR=2.06, 95% CI: 1.38-3.06) in patients with organ-confined bladder cancer. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 31190987-9 2019 Conclusions: Expression of PD-L1 on TCs was associated with muscle-invasive disease in patients with bladder cancer. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 36-39 CD274 molecule Homo sapiens 27-32 30296523-4 2019 PD-L1 expression on TCs was observed in 55.4% (129/233) of ESCC cases and was not associated with clinicopathological factors. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 30296523-8 2019 Our results showed that PD-L1 expression on TCs was an independent predictor of prognosis of ESCC patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 44-47 CD274 molecule Homo sapiens 24-29 30449485-7 2018 Discrepancies in PD-L1 expression on TCs and ICs between lung metastases and primary lesions were observed in 5 (11.4%, kappa = 0.23) and 9 (20.5%, kappa = 0.11) of the 44 cases, respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 37-40 CD274 molecule Homo sapiens 17-22 30449485-8 2018 PD-L1 expression on ICs was higher in lung metastases than paired primary tumors (p = 0.026), although the percentage of PD-L1-positive TCs was not significantly different between lung metastases and primary tumors (p = 0.767). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 136-139 CD274 molecule Homo sapiens 121-126 29673110-11 2018 About 37.3% cases (205/550) showed PD-L1 expression in TCs and/or TIICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 55-58 CD274 molecule Homo sapiens 35-40 29431467-13 2018 The majority of cases negative for PD-1 also lacked PD-L1 in TCs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 61-64 CD274 molecule Homo sapiens 52-57 29431467-15 2018 Strong correlations were observed in patients with elevated PD-1 expression in TILs and PD-L1 in TCs ( P = .01) and ICs ( P = .003). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 97-100 CD274 molecule Homo sapiens 88-93 29431467-19 2018 :: Expression of PD-1 in TILs correlates with PD-L1 expression in both TCs and ICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 71-74 CD274 molecule Homo sapiens 46-51 30304846-6 2018 There was a strong correlation between local recurrence and low PD-L1 expression on ICs (p = 0.0012), TCs (p = 0.013) or both (p = 0.000044), whereas all clinical parameters had no influence on local recurrence. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 102-105 CD274 molecule Homo sapiens 64-69 30304846-8 2018 High PD-L1 expression on both ICs and TCs was an independent favorable prognostic factor (p = 0.022; HR = 0.46; 95% CI = 0.24-0.89) for overall survival. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 38-41 CD274 molecule Homo sapiens 5-10 30216999-5 2018 In the latter, a high CD4+/CD8+ ratio, and combined PD-L1 expression >=1% TCs with a low CD8+ density, low CD33+ density, and a high CD4+ density correlated to worse overall survival. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 77-80 CD274 molecule Homo sapiens 52-57 30077124-9 2018 In the overall study population, PD-L1 was expressed on TCs and TIICs in 25% and 40% of cases, respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 56-59 CD274 molecule Homo sapiens 33-38 30077124-10 2018 The proportion of PD-L1-positive cases was significantly higher in stage I-III versus metastatic patients (32% versus 13%, p: 0.034 for TCs; 51.5% versus 21% for TIICs, p: 0.002). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 136-139 CD274 molecule Homo sapiens 18-23 29673110-12 2018 17.3% cases (95/550) showed PD-L1 expression in TCs, 34.5% (190/550) cases showed PD-L1 expression in TIICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 48-51 CD274 molecule Homo sapiens 28-33 28815764-10 2018 Interestingly, the highest percentages of PD-L1-positive TCs with the three antibodies were found in samples with cyclin-dependent kinase 6 (CDK6) amplification, with high amplification of proto-oncogene C-Myc (CMYC) or with cyclin D1-PI3 kinase subunit alpha (CCND1-PIK3CA) co-amplification. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 57-60 CD274 molecule Homo sapiens 42-47 29378266-6 2018 The prevalence of PD-L1 expression on TCs was 15.1% (29 of 192). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 38-41 CD274 molecule Homo sapiens 18-23 29405663-7 2018 RESULTS: The average PD-L1 positivity rate was 28% in TCs and 5% in ICs in surgical specimens (standard deviations of 37% and 7%, respectively), and 21% in TCs and 8% in ICs in cytology specimens (standard deviations of 33% and 15%, respectively). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 54-57 CD274 molecule Homo sapiens 21-26 29707344-7 2018 In the P53 (+) group, the rate of patients with PD-L1 (+) in TCs was significantly higher than in the P53 (-) group (85.3% vs. 45.5%, P=0.001). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 61-64 CD274 molecule Homo sapiens 48-53 29707344-8 2018 In addition, among the 45 patients who underwent adjuvant chemotherapy, DFS was significantly longer in patients with either PD-L1 (+) in TCs or P53 (+) (P=0.036 and 0.044, respectively). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 138-141 CD274 molecule Homo sapiens 125-130 29707344-10 2018 PD-L1 (+) in TCs and P53 (+) were reliable predictors for longer DFS and benefits from adjuvant therapy in resected cases. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 13-16 CD274 molecule Homo sapiens 0-5 29467945-8 2018 In SqCCs, the high expression of PD-L1 (defined as >=50% TC score) in TCs tended to be associated with early stage cancer. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 73-76 CD274 molecule Homo sapiens 33-38 29467945-11 2018 High PD-L1 positivity in TCs, especially in SqCCs, indicated that PD-1/PD-L1 targeted therapy may be a promising therapeutic approach. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 25-28 CD274 molecule Homo sapiens 5-10 29467945-11 2018 High PD-L1 positivity in TCs, especially in SqCCs, indicated that PD-1/PD-L1 targeted therapy may be a promising therapeutic approach. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 25-28 CD274 molecule Homo sapiens 71-76 28549836-10 2017 RESULTS: Prevalence of PD-L1 expression was 16.8% in TCs and 27.8% in ICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 53-56 CD274 molecule Homo sapiens 23-28 28549836-14 2017 Eleven (61.1%) of 18 amplified cores showed PD-L1 staining in < 5% of TCs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 73-76 CD274 molecule Homo sapiens 44-49 29025424-4 2017 RESULTS: We found that PD-L1 was expressed in gastric ulcer and in tumor cells (TCs), as well as in tumor-infiltrating immune cells (TIICs), but not in normal gastric mucosa or other gastric intraepithelial neoplastic tissues. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 80-83 CD274 molecule Homo sapiens 23-28 27629881-7 2017 RESULTS: PD-L1 expression on TCs and TIICs, MMR deficiency, and EBV positivity were identified in 22.8, 61.4, 5.1, and 5.1 % cases respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 29-32 CD274 molecule Homo sapiens 9-14 28969052-6 2017 The PD-L1 and PD-L2 positivity rates were 40.3% and 53.8% in TCs, respectively, and 60.0% and 60.9% in TIICs, respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 61-64 CD274 molecule Homo sapiens 4-9 28969052-7 2017 PD-L1 was up-regulated in EBV-infected GC patients in both TCs (P=0.009) and TIICs (P=0.003). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 59-62 CD274 molecule Homo sapiens 0-5 28978000-5 2017 PD-L1 expression on TCs was defined by the percentage of PD-L1 positive tumor cells (< 1%= IC0, >=1% but <5%=IC1, >=5 %=IC2/3), and was considered negative or positive for ICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 28978000-5 2017 PD-L1 expression on TCs was defined by the percentage of PD-L1 positive tumor cells (< 1%= IC0, >=1% but <5%=IC1, >=5 %=IC2/3), and was considered negative or positive for ICs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 57-62 28978000-7 2017 High PD-L1 expression (IC2/3) on TCs was more frequently seen in histologic subtypes of urothelial cancer compared to pure urothelial cancers (46.2% vs. 20.8%; p=0.002). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 33-36 CD274 molecule Homo sapiens 5-10 28978000-8 2017 PD-L1 expression on TCs in primary tumors (IC2/3 vs. IC0, median: 3.2 vs. 13.8 months, p=0.019) and metastatic sites (IC2/3 vs. IC0, median: 6.1 vs. 21.8 months, p=0.014) was associated with poor chemo-response, represented by significant shortened DSS. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 28137741-9 2017 Considering staining at any intensities for overall PD-L1 expression, 314 (32.0%), 204 (20.8%) and 141 (14.3%) tumor samples were positive for PD-L1 staining on TCs using cut-offs at >=1%, >=10% and >=25%, respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 161-164 CD274 molecule Homo sapiens 143-148 27322149-4 2016 PD-L1 was expressed in TCs of 18.4% and in TIICs of 83.3% of these patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 23-26 CD274 molecule Homo sapiens 0-5 27466552-3 2016 RESULTS: Among 40 patients, PD-L1 was expressed in tumor cells (TCs) of six (15%), tumor-infiltrating cells (ICs) of 16 (40%), and TCs and/or ICs cells of 18 (45%) patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 64-67 CD274 molecule Homo sapiens 28-33 27322149-6 2016 PD-L1 expressions in both TCs and TIICs were significantly associated with favorable overall survival, and combining their levels enhanced prognostic accuracy. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 26-29 CD274 molecule Homo sapiens 0-5 26980049-9 2016 PD-L1 expression by TILs and TCs correlated for SP142 (P = .023), and PD-L1 SP142 expression by TCs was associated with shorter overall survival (P = .016). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 96-99 CD274 molecule Homo sapiens 70-75 26822379-8 2016 Moreover, patients with response to NACT presented significantly reduced PD-L1 expression on TCs (p = 0.004). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 93-96 CD274 molecule Homo sapiens 73-78 34559865-8 2021 RESULTS: The expression rates of PD-L1 were 79.0%, 67.7%, and 46.8% on ICs, and 17.7%, 6.5%, and 12.9% on TCs using the 73-10, SP142, and E1L3N assays, respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 106-109 CD274 molecule Homo sapiens 33-38 34900743-11 2021 Conclusions: PD-L1 expression on TCs associated with improved survival in OPSCC. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 33-36 CD274 molecule Homo sapiens 13-18 34217914-6 2021 High PD-L1 expression was defined as expression on >=25 % of TCs or ICs based on first diagnostic biopsy or surgical resection. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 61-64 CD274 molecule Homo sapiens 5-10 34272092-5 2021 PD-L1 positivity in TCs was more frequent in high-grade than in low-grade tumors, while that in ICs was associated with lymphovascular space invasion, non-endometrioid histology, and deep myometrial invasion. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 34272092-6 2021 PD-L1 expression in both TCs and ICs was more frequent in POLE ultramutated and MMR-deficient subtypes than in p53-mutant and NSMP subtypes. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 25-28 CD274 molecule Homo sapiens 0-5 34272092-7 2021 PD-L1 positivity in TCs, but not in ICs or combined (CPS), was associated with a favorable prognosis in patients with high-risk endometrial cancer. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 34272092-4 2021 RESULTS: Positive PD-L1 staining in TCs (>=1%), ICs (>=1%), and in combination (CPS >=1) was detected in 14.0%, 37.3%, and 45.1% of the samples, respectively. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 36-39 CD274 molecule Homo sapiens 18-23 34454491-13 2021 CONCLUSION: Higher LAG-3 and PD-1 on TILs, and higher PD-L1 expression on TCs, and pathological type III were identified as independent risk factors for poorer DFS in NPC patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 74-77 CD274 molecule Homo sapiens 54-59 35596539-6 2022 There was a disagreement in PD-L1 expression on TCs between paired BM and PL lesions in 15 cases and on ICs in seven cases. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 48-51 CD274 molecule Homo sapiens 28-33 34326649-5 2021 B7-H3 expression in TCs was more frequent in squamous cell carcinoma, PD-L1-positive samples, and tissues from patients with lymph node metastasis; moreover, its expression was an independent predictor of shorter survival. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 70-75 35521773-7 2022 PD-L1 positivity was found in either TCs or TICs in 11.1% (6/54) of the patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 37-40 CD274 molecule Homo sapiens 0-5 35521773-9 2022 However, PD-L1 positivity in either TCs or TICs had no association with patient clinicopathological features. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 36-39 CD274 molecule Homo sapiens 9-14 34266881-8 2021 Intersite and intrasite reproducibility were assessed by linear fits to plots of cell densities, including %PDL1 expression by TCs and ICs in the breast and NSCLC TMAs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 127-130 CD274 molecule Homo sapiens 108-112 34136742-8 2021 SP142-based assays had overall low concordance with other approved assays when used to assess PD-L1 expression on TCs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 114-117 CD274 molecule Homo sapiens 94-99 34136742-9 2021 Analytical concordance for assessment of PD-L1 expression on immune cells was variable and generally lower than for PD-L1 expression on TCs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 136-139 CD274 molecule Homo sapiens 116-121 34136742-10 2021 CONCLUSION: A large body of evidence supports the potential interchangeability of 28-8-, 22C3-, and SP263-based assays for the assessment of PD-L1 expression on TCs in lung cancer. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 161-164 CD274 molecule Homo sapiens 141-146 35596539-8 2022 PD-L1 positivity on both TCs and ICs was associated with a better post-BM-surgery prognosis (p = 0.010; p = 0.041). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 25-28 CD274 molecule Homo sapiens 0-5 35596539-9 2022 Notably, PD-L1 positivity on TCs and a high level of intraepithelial CD8+ T cell infiltration could serve as an integrated biomarker that indicates longer survival time (p = 0.004) in LC patients. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 29-32 CD274 molecule Homo sapiens 9-14 35346570-7 2022 The expression of PD-L1 on TCs and/or TILs was associated with worse OS irrespectively of the antibody and the analyzed compartment. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 27-30 CD274 molecule Homo sapiens 18-23 35037417-8 2022 Survival analysis revealed that positive PD-L1 (p = 0.046) and PD-L2 (p = 0.028) expression on TCs was an independent risk factor for unfavourable disease-specific survival (DSS). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 95-98 CD274 molecule Homo sapiens 41-46 35346570-8 2022 Nevertheless, the best prognostic performance was noted for the combined assessment of PD-L1 expression on TCs and TILs in venous tumor thrombus with the use of 22c3 antibody. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 107-110 CD274 molecule Homo sapiens 87-92 33930847-8 2021 PD-L1 positivity in TCs and ICs was significantly less frequent in EGFR-mutated than in wild-type tumors. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 20-23 CD274 molecule Homo sapiens 0-5 35169863-3 2022 The TIL and M2 TAM densities were associated with the expression of PD-L1 on the two TCs (both P<0.0001) and ICs (both P<0.0001). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 85-88 CD274 molecule Homo sapiens 68-73 35169863-5 2022 However, there was no correlation between the percentage of PD-L1-positive TCs and the percentage of PD-L2-positive TCs (r=0.019; P=0.8049). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 75-78 CD274 molecule Homo sapiens 60-65 33196892-3 2021 PD-L1 expression in tumor cells (TCs) was classified as negative (TPS expression in < 1% of TCs), low (TPS in 1-49% of TCs), or high (TPS in >= 50% of TCs). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 33-36 CD274 molecule Homo sapiens 0-5 33196892-3 2021 PD-L1 expression in tumor cells (TCs) was classified as negative (TPS expression in < 1% of TCs), low (TPS in 1-49% of TCs), or high (TPS in >= 50% of TCs). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 92-95 CD274 molecule Homo sapiens 0-5 33782193-7 2021 DIA on mIF showed that PD-L1 commonly colocalised with CD68+ macrophages and CD8+ cytotoxic cells were closer to PD-L1-/CK+ tumour cells (TCs) than to PD-L1+/CK+ TCs in spatial distribution. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 138-141 CD274 molecule Homo sapiens 23-28 33071109-7 2021 RESULTS: Of the 97 specimens, 19.5% contained PD-L1-positive TCs, and 35.0% contained PD-L1-positive TILs. 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 61-64 CD274 molecule Homo sapiens 46-51 33071109-8 2021 Regarding clinicopathological factors, PD-L1-positive TCs and TILs were significantly associated with high-grade tumors (TCs, P = 0.01; TILs, P = 0.003). 9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide 54-57 CD274 molecule Homo sapiens 39-44